Apollo Hospitals Enterprise Ltd Q1 FY2025 Concall Summary

Key Takeaways

• Volume-led quarter, margin expansion on track: Healthcare Services EBITDA margin improved to 23.6% (up 50 bps QoQ) driven by 11% IP volume growth and 600 bps occupancy gains, while ARPOB growth was muted at 2% due to case mix.
• Apollo 24/7 pivots to profitability: GMV growth slowed to ~9% as the platform shifted to an omni-channel model with lower discounts, but pre-OPEX EBITDA margin improved to 13.6% (from 10.9% YoY) and cash losses halved. Management asked for forbearance on growth until Q3/Q4.
• 100 bps margin expansion committed for FY25: Four levers identified: payer mix improvement, international focus, case mix shift toward surgical volumes, and a 4% tariff distribution within the next four quarters.
• Bed expansion pipeline is concrete: Four new hospitals (Gurgaon, Kolkata, Hyderabad, Pune) adding 1,500 beds to be operationalized within five quarters, with FY26 margins expected to absorb 100–150 bps of drag from new-unit ramp-ups.
• What to watch next quarter: Whether the 24/7 GMV growth re-accelerates as guided, the pace of the 4% tariff distribution, and any recovery in Bangladesh international patient volumes.

Volume Growth & Occupancy

• IP volumes drove the quarter: Inpatient volumes grew 11% YoY across all markets, with high-end tertiary care (cardiac, oncology, neuro, gastro) and higher secondary specialties both contributing. Occupancy rose over 600 bps YoY to 68%.
• Insurance penetration is the structural driver: Insurance coverage reached ~47%, and deliberate corporate outreach is converting employees covered by private insurance (a market growing 35%). Insurance patients carry equal or higher ARPOB than walk-in cash patients because they opt for higher room categories.
• OP-to-IP funnel is working: Strong OP volume pickup in AP/Telangana (~50%) and Karnataka (~40%) was driven by on-site health checkups and corporate outreach, feeding into inpatient volume at a ~4% conversion rate.
• Occupancy assumption for the year: Management indicated similar occupancy levels to Q1 can be assumed for the rest of the year, with a preference to improve further.

A Krishnan: "ARPOB is just a derived number, which is a combination of both occupancies and ALOS. So, I think from the perspective of volume, you know, you are seeing the volume growth and if it's volume into value, we are not going to be seeing any deterioration in our revenue pick up because of insurance. On the contrary, it will only be positive."

ARPOB & Case Mix Dynamics

• ARPOB growth muted at 2% YoY: The softness was driven by a higher medical mix with fewer surgical volumes and electives this quarter, not by insurance. Oncology growth (chemotherapy) carries lower ARPOB than surgical oncology, but flow-through to margins is visible.
• ARPOB is not the margin lever: Management explicitly stated ARPOB is not the primary lever for EBITDA growth. The focus is on volume growth and value growth (volume × ARPOB), with inpatient volumes up 10% and ARPOB up 4% combining to drive revenue.
• Tariff distribution of 4% planned: A 4% tariff increase is expected to be distributed within the next four quarters, contributing to the 100 bps margin expansion target. Inflation of 4–5% in ARPOB is something management intends to continue over time.
• Regional variation exists: ARPOB growth was muted or declining in most regions except the north.

A. Krishnan: "ARPOB is not as much a lever for our EBITDA growth etc., because average revenue per inpatient is gone by 4%, inpatient volumes have gone by 10%. Volume into value equal to revenue growth."

Margin Trajectory & Levers

• Healthcare Services EBITDA margin at 23.6%: This represents a 50 bps QoQ improvement over Q4 FY25 (23.1%, after adding doctor and marketing costs). Higher IT costs and cybersecurity investments (0.25–0.3% impact) were absorbed in the quarter.
• Four levers for 100 bps expansion over 3–4 quarters: Payer mix improvement from insurance penetration, international patient focus (better ARPOB), case mix improvement toward surgical volumes and electives, and the 4% tariff distribution.
• Doctor hiring is an investment, not a drag: 102 doctors were added in Q1 (84 in the prior quarter), many senior or star doctors, with an incremental cost of ₹50 crore quarter-to-quarter versus the same period last year. These doctors are becoming more productive and are expected to improve margins.
• Operating leverage still to come: Higher occupancy has not yet fully translated to profitability because of cost absorption; operating leverage is expected to play out in coming quarters.
• FY26 margin outlook: From the FY25 exit level, expect 100–150 bps lower due to new bed additions coming online, though losses from new units are not expected to be significant.

Suneeta Reddy: "The first, of course, is payer mix, and we have spoken about that and how insurance has really helped us in this sense, contributing to not only volumes but margins."

Apollo 24/7: Growth Reset & Path to Breakeven

• GMV growth slowed to ~9%: The deceleration from prior run-rates was driven by a deliberate operating model shift from pure digital origination to an omni-channel approach, plus a reduction in marketing spends and discounts. Pharmacy was impacted for 5–6 months; July numbers have started picking up.
• Pre-OPEX EBITDA margin improved to 13.6%: Up from 10.9% YoY, driven by a better pharmacy mix (35–36% vs 32%) and new margin-accretive verticals: insurance, digital therapeutics, and app monetization. Cash losses (ex-ESOPs) halved to ₹97 crore from ₹152 crore YoY.
• Marketing costs slashed: Marketing expenses reduced from the ₹150–₹180 crore range to around ₹80 crore, with customer acquisition cost now in the ₹250–₹400 range. Management believes this cost advantage is unique to Apollo given its 6,000 offline outlets and hospital network as sourcing points.
• Consult business is the feeder: OPD consults grew from ~100,000 to 150,000–170,000 per quarter, feeding into the pharmacy and diagnostic businesses.
• 50% GMV growth guidance maintained: Management is not revising the ~₹4,000 crore GMV target and expects the growth story to pick up sustainably in Q3 or Q4 FY25.
• Breakeven on track: The digital business is expected to breakeven within the next 6–7 quarters (consistent with Q4 FY24 guidance). Apollo HealthCo as a whole achieved breakeven one quarter early, reporting positive EBITDA of ₹23 crore.

Madhivanan B: "I would ask for forbearance over the next, maybe this quarter and the next quarter before the growth story starts picking up in a sustainable manner."

Expansion Pipeline: Beds, Stores & Insurance

• Four new hospitals in five quarters: Greenfield hospitals in Gurgaon, Kolkata, Hyderabad, and Pune will add 1,500 beds. Brownfield expansion in Mysore (140 beds) is also underway. Next year (FY26) will see good additions in existing markets like Calcutta and Gurugram.
• Pharmacy store rollout on track: 44 stores were added in Q1 (election season caused slight delays in approvals). The full-year target of 500–550 stores remains on track, with Q2 already ramping up well.
• Insurance business awaiting approval: IRDAI approval for corporate agency (health and term) is expected by October, with full-fledged launch to follow. The cost of acquisition is expected to be much lower than standalone digital players.
• International patient volumes: Management is hopeful Bangladesh volumes will recover quickly and is actively exploring other international markets, an effort underway for the past 1–2 years.

Diagnostics & Other Businesses

• Diagnostics margin dipped sequentially: The decline was due to seasonal impact and investments in specialty manpower and new segments. Q4 had one-off gains from year-end reversals (turnover discounts of ~₹2.6–₹3 crore, leave encashment of ~₹1.5 crore) that did not repeat. Revenue and margin growth are expected from this quarter onward.
• Diagnostics poised for growth: Investment in new capacity, an expanded test menu, and improved margins underpin the outlook for strong healthy growth.
• Apollo HealthCo positive EBITDA: The entity reported positive EBITDA of ₹23 crore, extending its trajectory. Transaction integration and healthy offline pharmacy growth are expected to drive it toward its stated strategic intent over the next three years.

Guidance & Commitments

Key Metrics